Form 4 for ABCL AbCellera Biologics Inc.
Accepted 2021-09-03 00:00:00 ET · period of report 2021-09-01 · accession 0001209191-21-054749 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-03 | 2021-09-01 | ABCL | Falconer Ester | CTO | M - OptEx | $16.89 | +875.0K | 875.0K | New | +$14.78M |
| D | 2021-09-03 | 2021-09-01 | ABCL | Falconer Ester | CTO | M - OptEx | $0.00 | -875.0K | 875.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-09-01 | M | A | 875,000 | $16.89 | 875,000 | D | — | — | |
| 2 | Derivative | Share option (right to buy) | 2021-09-01 | M | D | 875,000 | $0.00 | 875,000 | D | $0.31 · — to 2029-01-01 | 875,000 Common Shares | (F1) The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on January 1, 2020, subject to the Reporting Person's continuous service to the Issuer on each such date |